Evidence supporting risk reduction A growing body of observational data suggests that TZDs are associated with a favorable trend towards reduced CRC risk among antidiabetic drugs.
← all excerpts
Pharmacological mechanisms and clinical impacts of antidiabetic drugs on colorectal cancer risk: a systematic review.
1
—
—